- Home
- GMAB
GMAB
Genmab A/S ADS
as 07-26-2024 4:00pm EST
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
| Founded: | 1999 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 17.9B | IPO Year: | N/A |
| Target Price: | $46.00 | AVG Volume (30 days): | 680.8K |
| Analyst Decision: | Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.20 | EPS Growth: | 5.08 |
| 52 Week Low/High: | $24.53 - $42.72 | Next Earning Date: | 08-08-2024 |
| Revenue: | $2,570,622,287 | Revenue Growth: | 16.71% |
| Revenue Growth (this year): | 23.05% | Revenue Growth (next year): | 18.11% |
Latest Genmab A/S ADS News
GMAB Breaking Stock News: Dive into GMAB Ticker-Specific Updates for Smart Investing
Zacks
a day ago
GMAB vs. CSLLY: Which Stock Is the Better Value Option?
GlobeNewswire
10 days ago
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
MT Newswires
12 days ago
RBC Upgrades Genmab to Outperform From Sector Perform, Keeps Price Target at DKK2,400
Zacks
17 days ago
GMAB or TECH: Which Is the Better Value Stock Right Now?
Zacks
18 days ago
GMAB vs. TECH: Which Stock Is the Better Value Option?
Zacks
25 days ago
AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use
MT Newswires
a month ago
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment
Business Wire
a month ago
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma
Compare GMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GMAB Genmab A/S ADS - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.